Alexion, Investors Reach $125 Million Deal in Soliris Sales Suit

Alexion Pharmaceuticals Inc. and investors who sued the drugmaker agreed on a $125 million settlement that would put an end to claims that the company boosted its sales of commercial drug Soliris with illegal and unethical sales practices, a court filing says.

The parties seek a judge’s approval for the deal, which would resolve the proposed class action filed in 2016, alleging the company concealed its sales practices from investors for more than four years, according to a motion filed Wednesday in the US District Court for the District of Connecticut.

Investors alleged that Alexion pressured or frightened patients into ...